A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients=60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)

被引：1

作者：

Zeidner, Joshua F. ^{[1
]}

Foster, Matthew C. ^{[2
]}

Johnson, Mary ^{[3
]}

Huang, Ying ^{[4
]}

Swords, Ronan T. ^{[5
]}

Stein, Eytan ^{[6
]}

Foran, James M. ^{[7
]}

Baer, Maria R. ^{[8
]}

Stock, Wendy ^{[9
]}

Madanat, Yazan F. ^{[10
]}

Kovacsovics, Tibor ^{[11
]}

Olin, Rebecca L. ^{[12
]}

Blum, William G. ^{[13
]}

Schiller, Gary J. ^{[14
]}

Lin, Tara L. ^{[15
]}

Redner, Robert L. ^{[16
]}

Al-Mansour, Zeina ^{[17
]}

Curran, Emily K. ^{[18
]}

Heerema, Nyla A. ^{[19
]}

Martycz, Molly ^{[20
]}

Rosenberg, Leonard ^{[21
]}

Marcus, Sonja ^{[3
]}

Yocum, Ashley O. ^{[3
]}

Chen, Timothy ^{[22
]}

Stefanos, Mona ^{[20
]}

Druggan, Franchesca ^{[23
]}

Burd, Amy ^{[24
]}

Levine, Ross L. ^{[25
]}

Druker, Brian J. ^{[26
]}

Borate, Uma ^{[27
]}

Byrd, John C. ^{[28
]}

Mims, Alice S. ^{[4
]}

机构：

[1] UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA

[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA

[3] Leukemia & Lymphoma Soc, Rye Brook, NY USA

[4] Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA

[5] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol Med Oncol, Portland, OR 97201 USA

[6] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA

[7] Mayo Clin, Div Hematol Oncol & Blood & Marrow Transplanat &, Jacksonville, FL 32224 USA

[8] Univ Maryland, Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA

[9] Univ Chicago, Chicago, IL 60637 USA

[10] Univ Texas Southwestern, Dept Internal Med, Div Hematol Oncol, Dallas, TX USA

[11] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA

[12] Univ Calif San Francisco, San Francisco, CA 94143 USA

[13] Emory Univ, Dept Hematol & Oncol, Winship Canc Inst, Atlanta, GA 30322 USA

[14] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[15] Univ Kansas, Westwood, KS USA

[16] UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[17] Univ Florida, UF Hlth Shands Hosp, Gainesville, FL USA

[18] Univ Cincinnati, Cincinnati, OH USA

[19] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA

[20] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH 43210 USA

[21] Leukemia & Lymphoma Soc, Mt Laurel, NJ USA

[22] Ohio State Univ, Coll Med, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA

[23] Ohio State Univ, Columbus, OH 43210 USA

[24] Leukemia & Lymphoma Soc, White Plains, NY USA

[25] Mem Sloan Kettering Canc Ctr, Ctr Hematol Malignancies, 1275 York Ave, New York, NY 10021 USA

[26] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Med Oncol, Portland, OR 97201 USA

[27] Ohio State Univ, Div Hematol, Columbus, OH USA

[28] Univ Cincinnati, Dept Internal Med, Cincinnati, OH USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-166715

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：9070 / 9073

页数：4

共 22 条

[1] Lemzoparlimab (lemzo) with venetoclax (ven) and/or azacitidine (aza) in patients (pts) with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS): A phase 1b dose escalation study.
Daver, Naval Guastad
Stevens, Don A.
Hou, Jing-Zhou
Yamauchi, Takahiro
Moshe, Yakir
Fong, Chun Yew
Marzocchetti, Angela
Adamec, Ryan
Patel, Maulik
Lambert, Stacie
Wu, Kevin
Rollig, Christoph
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[2] The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study
Issa, Ghayas C.
Aldoss, Ibrahim
DiPersio, John F.
Cuglievan, Branko
Stone, Richard M.
Arellano, Martha L.
Thirman, Michael J.
Patel, Manish R.
Dickens, David
Shenoy, Shalini
Shukla, Neerav
Rosen, Galit
Bagley, Rebecca G.
Meyers, Michael L.
Madigan, Kate
Ordentlich, Peter
Gu, Yu
Smith, Steven
McGeehan, Gerard M.
Stein, Eytan
BLOOD, 2022, 140
[3] OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)
Ravandi, Farhad
Carraway, Hetty E.
Taningco, Lilia
Dilley, Kimberley
Laille, Eric
Gong, Jing
de Menezes, Daniel Lopes
Wei, Andrew H.
BLOOD, 2021, 138
[4] Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse
Arora, Sankalp
Senapati, Jayastu
Loghavi, Sanam
Reville, Patrick K.
Wang, Bofei
Kadia, Tapan M.
Dinardo, Courtney D.
Pemmaraju, Naveen
Yilmaz, Musa
Jabbour, Joseph E.
Short, Nicholas J.
Montalban-Bravo, Guillermo
Maiti, Abhishek
Tang, Guilin
Sasaki, Koji
Borthakur, Gautam
Alvarez, Joie
Pierce, Sherry
Gonzalez, Graciela M. Nogueras
Ning, Jing
Issa, Ghayas C.
Andreeff, Michael
Ravandi, Farhad
Garcia-Manero, Guillermo
Abbas, Hussein A.
Daver, Naval
BLOOD, 2024, 144 : 736 - 737
[5] Mutant Isocitrate Dehydrogenase (mIDH) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
DiNardo, Courtney D.
Stein, Anthony S.
Fathi, Amir T.
Montesinos, Pau
Odenike, Olatoyosi
Kantarjian, Hagop M.
Stone, Richard M.
Koralek, Daniel O.
Van Oostendorp, Jason
Gong, Jing
Gupta, Ira
Vyas, Paresh
BLOOD, 2017, 130
[6] A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Erba, Harry P.
Levy, Moshe Y.
Vasu, Sumithira
Stein, Anthony S.
Fathi, Amir T.
Maris, Michael B.
Advani, Anjali
Faderl, Stefan
Smith, Scott E.
Wood, Brent L.
Walter, Roland B.
Yang, Jay
Donnellan, William B.
Feldman, Eric J.
Voellinger, Jenna L.
Ravandi, Farhad
BLOOD, 2016, 128 (22)
[7] Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
Borate, Uma
Li, Rui
Huang, Ying
Swords, Ronan T.
Traer, Elie
Stein, Eytan
Foran, James M.
Baer, Maria R.
Duong, Vu H.
Stock, Wendy
Odenike, Olatoyosi
Patel, Prapti
Collins, Robert H.
Madanat, Yazan F.
Kovacsovics, Tibor
Deininger, Michael W.
Smith, Catherine
Olin, Rebecca L.
Arellano, Martha L.
Blum, William G.
Schiller, Gary J.
Lin, Tara L.
Foster, Matthew C.
Boyiadzis, Michael M.
Redner, Robert L.
Al-Mansour, Zeina
Curran, Emily K.
Heerema, Nyla A.
Gana, Theophilus J.
Martycz, Molly
Rosenberg, Leonard
Marcus, Sonja
Yocum, Ashley O.
Chen, Timothy
Stefanos, Mona
Druggan, Franchesca
Burd, Amy
Levine, Ross L.
Druker, Brian J.
Byrd, John C.
Mims, Alice S.
BLOOD, 2022, 140 : 6200 - 6203
[8] Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial
Stein, Eytan M.
Huang, Ying
Borate, Uma
Baer, Maria R.
Stock, Wendy
Kovacsovics, Tibor
Blum, William
Schiller, Gary J.
Olin, Rebecca L.
Foran, James M.
Litzow, Mark
Lin, Tara
Patel, Prapti A.
Foster, Matthew C.
Boyiadzis, Michael
Collins, Robert H.
Vergilio, Jo-Anne
Heerema, Nyla A.
Rosenberg, Leonard
Yocum, Ashley Owen
Chen, Timothy
Druggan, Franchesca
Marcus, Sonja
Stefanos, Mona
Chervin, Jordan
Shoben, Abigail
Druker, Brian J.
Burd, Amy
Byrd, John C.
Levine, Ross L.
Mims, Alice S.
BLOOD, 2020, 136
[9] A Phase 1b Study of Vadastuximab Talirine (33A) in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Walter, R.
Erba, H.
Ravandi, F.
ANNALS OF HEMATOLOGY, 2017, 96 : S69 - S69
[10] Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study
Roboz, Gail J.
Pabst, Thomas
Aribi, Ahmed
Brandwein, Joseph M.
Dohner, Hartmut
Fiedler, Walter
Gandini, Domenica
Geddes, Michelle
Hou, Jing-Zhou
Howes, Angela J.
Hultberg, Anna
Huselton, Eric
Jacobs, Julie
Kane, Colleen
Lech-Maranda, Ewa
Louwers, Marieke
Nottage, Kerri
Platzbecker, Uwe
Rampal, Raajit
Salman, Mariya
Shah, Priya
Stevens, Don
Stuart, Monic
Subklewe, Marion
Sumbul, Anne
Wang, Eunice S.
Wierzbowska, Agnieszka
Yao, Bin
Yee, Karen
Kantarjian, Hagop
Borthakur, Gautam
BLOOD, 2021, 138

← 1 2 3 →